Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Natera, Inc. - Common Stock (NQ:NTRA)

363.76 UNCHANGED
Delayed Quote Updated: 4:00 PM EST, Nov 5, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Natera, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
24 25 Next >
News headline image
What Natera (NTRA) Said on Its Q3 Earnings Call ↗
Natera (NASDAQ:NTRA) raised its full-year revenue forecast after reporting a 34% increase in third-quarter revenue, as demand for its cancer-monitoring tests grew and the company announced a change in... 
Via MarketBeat
Topics Earnings
Natera (NASDAQ:NTRA) Q3 Revenue Beat Overshadowed by Profitability Miss and Selloff ↗
Via Chartmill
After-Hours Market Movers for Nov. 5, 2026: Gainers and Losers ↗
Via Chartmill
News headline image
Natera (NASDAQ:NTRA) delivers impressive Q3 2026 but stock drops 19.7%
Genetic testing company Natera (NASDAQ:NTRA) reported Q3 2026 results exceeding the market’s revenue expectations, with revenue up 34.1% year on year to $794... 
Via StockStory
News headline image
Natera Announces Leadership Transition
From Natera, Inc.
Via Business Wire
News headline image
Natera Reports Third Quarter 2026 Financial Results
From Natera, Inc.
Via Business Wire
News headline image
Signatera™ Monitoring During First-Line Immunotherapy Showed ctDNA Clearance is Associated with Long-Term Survival Across Four Metastatic Cancers
From Natera, Inc.
Via Business Wire
News headline image
Signatera™ in Head and Neck Cancer: Three New Publications Demonstrate Strong Clinical Performance and Actionability
From Natera, Inc.
Via Business Wire
News headline image
Natera (NTRA) to report earnings tomorrow: here is what to expect
Genetic testing company Natera (NASDAQ:NTRA) will be announcing earnings results this Thursday after the bell. Here’s what to expect. Natera beat analysts’ r... 
Via StockStory
Topics Artificial Intelligence
News headline image
Medicare Expands Coverage for Signatera™ MRD Test in Hepatocellular Carcinoma
From Natera, Inc.
Via Business Wire
News headline image
Natera to Report its Third Quarter Results on November 5, 2026
From Natera, Inc.
Via Business Wire
News headline image
Signatera™ Genome with Phased and Structural Variants Highlighted in ESMO Presidential Symposium, Supporting the Critical Role of MRD-Guided Treatment in Bladder Cancer
From Natera, Inc.
Via Business Wire
News headline image
Natera Shares Real-World Analyses and Data at ASN Kidney Week 2026, Highlighting the Critical Need for Genetic Testing with Renasight™
From Natera, Inc.
Via Business Wire
News headline image
Stanley Druckenmiller Has Bet Big on This 1 Healthcare Stock. Here's Why I Disagree. ↗
The business is promising, but the valuation today has gone to the stratosphere. 
Via The Motley Fool
Topics Artificial Intelligence
News headline image
Why Natera (NTRA) Stock Is Up Today
What Happened? Shares of genetic testing company Natera (NASDAQ:NTRA) jumped 2.4% in the afternoon session after the company announced that incorporating pha... 
Via StockStory
News headline image
ESMO 2026 Presentations Deepen the Evidence Base for Natera’s Oncology Portfolio and Leadership in Ultrasensitive MRD Technology
From Natera, Inc.
Via Business Wire
News headline image
Natera’s Signatera™ MRD Test Named to TIME’s List of the Best Inventions of 2026
From Natera, Inc.
Via Business Wire
News headline image
Natera and TransCode Therapeutics to Collaborate on Phase 2a Trial of TTX-MC138 in Colorectal Cancer
From Natera, Inc.
Via Business Wire
News headline image
Why Natera (NTRA) Stock Is Up Today
What Happened? Shares of genetic testing company Natera (NASDAQ:NTRA) jumped 1.7% in the morning session after the U.S. Food and Drug Administration granted ... 
Via StockStory
News headline image
FDA Grants Breakthrough Device Designation for Natera’s Multi-Cancer Early Detection Assay
From Natera, Inc.
Via Business Wire
News headline image
3 Market-Beating Stocks with Competitive Advantages
Stocks that outperform the market usually share key traits such as rising sales, expanding margins, and increasing returns on capital. The select few that ca... 
Via StockStory
News headline image
Natera Announces Randomized, Signatera™-Guided Interventional Study in Melanoma
From Natera, Inc.
Via Business Wire
News headline image
New Signatera™ Data Presented at ASTRO Conference, Highlights Utility for Radiation Oncologists
From Natera, Inc.
Via Business Wire
News headline image
1 Unpopular Stock That Deserves Some Love and 2 Facing Challenges
When Wall Street turns bearish on a stock, it’s worth paying attention. These calls stand out because analysts rarely issue grim ratings on companies for fea... 
Via StockStory
News headline image
Alliance Foundation Trials and Natera Announce AFT-70 NAVIGATE: a Global, Randomized, Phase III Trial Evaluating Genentech’s Oral Selective Estrogen Receptor Degrader (SERD) with Signatera™ MRD-Guided CDK4/6 Inhibitor Therapy in Breast Cancer
From Natera, Inc.
Via Business Wire
News headline image
2 Growth Stocks to Stash and 1 That Underwhelm
Growth boosts valuation multiples, but it doesn’t always last forever. Companies that cannot maintain it are often penalized with large declines in market va... 
Via StockStory
News headline image
1 Unprofitable Stock to Target This Week and 2 We Question
Unprofitable companies can burn through cash quickly, leaving investors exposed if they fail to turn things around. Without a clear path to profitability, th... 
Via StockStory
News headline image
Stocks making big moves yesterday: AutoZone, Natera, Shopify, Twilio, and Lennar
Check out the companies making headlines yesterday: AutoZone (NYSE:AZO): Auto parts and accessories retailer AutoZone (NYSE:AZO) rose by 6.1% on Tuesday afte... 
Via StockStory
Topics Artificial Intelligence
News headline image
Why Is Natera (NTRA) Stock Soaring Today
What Happened? Shares of genetic testing company Natera (NASDAQ:NTRA) jumped 5.2% in the afternoon session after the company announced that Japan's Pharmaceu... 
Via StockStory
News headline image
Signatera™ Receives Regulatory Approval in Japan as a Companion Diagnostic in Muscle-Invasive Bladder Cancer
From Natera, Inc.
Via Business Wire
< Previous 1 2 3 4 5 6 7 8 9
...
24 25 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.